May 7, 2018

Alere Technologies AS   
Annie Wright   
Senior Manager, Regulatory Affairs   
Kjelsaasveien 161   
PO Box 6863 Rodeloekka   
NO-0504 Oslo   
Norway

Re: K180296 Trade/Device Name: Afinion HbA1c Dx Regulation Number: 21 CFR 862.1373 Regulation Name: Hemoglobin A1c test system Regulatory Class: Class II Product Code: PDJ Dated: February 5, 2018 Received: February 6, 2018

Dear Annie Wright:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR

803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Kellie B. Kelm -S

Courtney H. Lias, Ph.D.GPS Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

20   
20 20 20   
20   
![](images/64b18a4a5bbeb4e91bb3306795b4d945537fb8d440bca89b4f4389e46c9891cb.jpg)
20   
20 20 20 20 20   
20 E

20   

<table><tr><td>Food and Drug Administration Indications for Use</td><td>Expiration Date: 06/30/2020 See PRA Statement below.</td></tr><tr><td>510(k) Number (if known)</td><td></td></tr><tr><td>k180296</td><td></td></tr><tr><td>Device Name</td><td></td></tr><tr><td>Afinion™M HbA1c Dx</td><td></td></tr><tr><td></td><td></td></tr><tr><td>Indications for Use (Describe)</td><td></td></tr></table>

  
20 20

# Afinion™ HbA1c Dx Premarket Notification

# 510(k) SUMMARY-k180296

# GENERAL INFORMATION

Applicant Name:

Alere Technologies AS Kjelsaasveien 161   
PO Box 6863 Rodeloekka NO-0504 Oslo   
Norway   
Establishment #9613069

# Company Contact:

Annie Wright   
Senior Manager, Regulatory Affairs   
Phone: (858) 805-2316   
Email: annie.wright@alere.com

Date Prepared:

April 26, 2018

# DEVICE IDENTIFICATION

Trade or Proprietary Names: Afinion™ HbA1c Dx

Common Name:

HbA1c test

Device Classification Name: Hemoglobin A1c Test System

Product Codes:

PDJ

Regulatory Class:

Class II (Special Controls)

Classification Regulation:

21 CFR 862.1373

Predicate Device: Cobas C501 Tina-Quant HbA1cDx Gen.3 assay (k121610)

# DEVICE DESCRIPTION

The Afinion™ HbA1c Dx is a fully automated boronate affinity assay for the determination of the percentage of hemoglobin A1c in human whole blood. The Afinion™ HbA1c Dx is a modification of the existing device, Alere Afinion™ HbA1c for use with the Alere Afinion™ AS100 Analyzer, with the addition of a diagnostic intended use.

The test begins with a blood sample collected with the integrated sampling device before the test cartridge is placed in the cartridge chamber of the Alere Afinion™ AS100 Analyzer. The sample is then automatically diluted and mixed with a solution that releases hemoglobin from the erythrocytes. After the hemoglobin is precipitated, the sample mixture is transferred to a blue boronic acid conjugate which binds to the cis-diols of glycated hemoglobin. This reaction mixture is soaked through a filter membrane and all precipitated hemoglobin, conjugate-bound and unbound (i.e. glycated and non-glycated hemoglobin) remains on the membrane. Excess conjugate is removed with a washing reagent. The analyzer measures the reflectance of the precipitate on the membrane as blue (glycated hemoglobin) and red (total hemoglobin) color intensities. The analyzer calculates a ratio proportional to the percentage of HbA1c in the sample and displays as the $\%$ HbA1c (NGSP).

# INTENDED USE

Afinion™ HbA1c Dx is an in vitro diagnostic test for quantitative determination of glycated hemoglobin ( $\%$ hemoglobin A1c, HbA1c) in human venous and capillary whole blood.

This test is to be used as an aid in the diagnosis of diabetes and as an aid in identifying patients who may be at risk for developing diabetes.

The measurement of $\%$ HbA1c is recommended as a marker of long-term metabolic control in persons with diabetes mellitus.

# COMPARISON WITH PREDICATE

<table><tr><td rowspan=1 colspan=1>Attribute</td><td rowspan=1 colspan=1>Predicate DeviceCobas C501 Tina-Quant HbA1cDx Gen.3assay (k121610)</td><td rowspan=1 colspan=1>Candidate DeviceAfinionTM HbA1c Dx</td></tr><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative determinationof hemoglobin A1c for the diagnosis of diabetesand as an aid in identifying patients who maybe at risk for developing diabetes</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Userenvironment</td><td rowspan=1 colspan=1>For use by health care professionals in clinicallaboratories</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Anticoagulated venous blood</td><td rowspan=1 colspan=1>Anticoagulated venous orcapillary blood</td></tr><tr><td rowspan=1 colspan=1>Anticoagulants</td><td rowspan=1 colspan=1>Li-Heparin, K2-EDTA, K3-EDTA, KF/Na2-EDTA, Na-Heparin, NaF/K-Oxalate andNaF/Na2-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td></tr><tr><td rowspan=1 colspan=1>Units ofmeasurement</td><td rowspan=1 colspan=1>% HbA1c (DCCT/NGSP)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storagerequirements</td><td rowspan=1 colspan=1>2-8°C until expiration date</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Standardization</td><td rowspan=1 colspan=1>Traceable to the International Federation ofClinical Chemistry and Laboratory Medicine(IFCC) and Diabetes Control andComplications Trial (DCTT) reference method.Certified via the National GlycohemoglobinStandardization Program (NGSP).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected values</td><td rowspan=1 colspan=1>Protocol 1 (IFCC)20-42 mmol/mol HbA1cProtocol 2 (DCCT/NGSP)4.0 - 6.0 %HbA1c</td><td rowspan=1 colspan=1>DCCT/NGSP4.0 - 6.0 %HbA1c</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Assay principle</td><td rowspan=1 colspan=1>HbA1c determination by turbidimetricinhibition immunoassay method.Hemoglobin determination by converting to aderivative with a characteristic absorptionspectrum which is measured bi-chromatically.</td><td rowspan=1 colspan=1>Boronate affinity assay.Hemoglobin determination byreflectance measurements ofblue conjugate of glycatedhemoglobin and red totalhemoglobin.</td></tr><tr><td rowspan=1 colspan=1>Hardware</td><td rowspan=1 colspan=1>Cobas c501</td><td rowspan=1 colspan=1>Alere AfinionT AS100Analyzer</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Provided by manufacturer</td><td rowspan=1 colspan=1>Calibration by user notrequired; factory calibrated</td></tr><tr><td rowspan=1 colspan=1>Reporting range</td><td rowspan=1 colspan=1>4.220.1 % HbA1c</td><td rowspan=1 colspan=1>4.0015.00 % HbA1c</td></tr></table>

# PERFORMANCE CHARACTERISTICS

1. Precision/Reproducibility

A. Precision - Internal

The precision of the Afinion™ HbA1c Dx was evaluated based on CLSI guideline EP05-A3. Four levels of HbA1c in anticoagulated venous whole blood patient samples at the following targeted HbA1c values - 5, 6.5, 8 and $1 2 \ \%$ HbA1c - were utilized in the study. Three test cartridge lots were included in the study. Two replicates of venous whole blood were tested twice a day for twenty days with each of the three lots on three Alere Afinion™ AS100 Analyzers.

Table 1a: Within-laboratory precision - results from analyzer 1 $( \mathrm { n } { = } 2 4 0 ) ,$ )   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.13</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>1.63</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.53</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.114</td><td rowspan=1 colspan=1>1.74</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.09</td><td rowspan=1 colspan=1>0.082</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>1.17</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.33</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>0.149</td><td rowspan=1 colspan=1>1.32</td></tr></table>

Table 1b: Within-laboratory precision - results from analyzer 2 $( \mathrm { n } { = } 2 4 0 )$ )   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.11</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>1.63</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.53</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.106</td><td rowspan=1 colspan=1>1.62</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.01</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>1.04</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.17</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>0.142</td><td rowspan=1 colspan=1>1.27</td></tr></table>

Table 1c: Within-laboratory precision - results from analyzer 3 $( \mathrm { n } { = } 2 4 0 )$ )   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.18</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>1.43</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.58</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>1.27</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.08</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.116</td><td rowspan=1 colspan=1>1.43</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.30</td><td rowspan=1 colspan=1>0.114</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.155</td><td rowspan=1 colspan=1>1.37</td></tr></table>

Table 1d: Within-laboratory precision – all analyzers combined $( \mathrm { n } { = } 7 2 0 )$ )   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Betweenanalyzer</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.14</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>1.64</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.55</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>1.51</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.06</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.106</td><td rowspan=1 colspan=1>1.31</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.26</td><td rowspan=1 colspan=1>0.101</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>0.160</td><td rowspan=1 colspan=1>1.42</td></tr></table>

# B. Precision – External (Venous Whole Blood)

The precision of the Afinion™ HbA1c Dx was evaluated externally. Four levels of HbA1c in anticoagulated venous whole blood patient samples at the following targeted HbA1c values: 5, 6.5, 8 and $1 2 \ \%$ HbA1c -were evaluated at each of three study sites. Three test cartridge lots were included in the study. Four replicates of venous whole blood were analyzed twice a day for ten days with each of the three lots at each of the three sites, utilizing three Alere Afinion™ AS100 Analyzers.

Table 2: External precision results from 3 sites combined. Root Mean Squared SD and $\% \mathrm { C V }$ . Between analyzer precision component from internal study added.   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Betweenanalyzer</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.02</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>1.21</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>1.78</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.41</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>1.48</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.18</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.111</td><td rowspan=1 colspan=1>1.36</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>12.09</td><td rowspan=1 colspan=1>0.118</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>0.147</td><td rowspan=1 colspan=1>1.22</td></tr></table>

Table 3: External precision results from 3 sites combined (abbreviated version of Table 5). Root Mean Squared $\% \mathrm { C V }$ . Between analyzer precision component from internal study added.   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>External Precision Study</td><td rowspan=2 colspan=1>Total %CV</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Repeatability%CV</td><td rowspan=1 colspan=1>Between-run %CV</td><td rowspan=1 colspan=1>Between-day %CV</td><td rowspan=1 colspan=1>Between-lot %CV</td><td rowspan=1 colspan=1>Between-analyzer %CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>1.21</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>1.78</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.48</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>1.36</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>1.22</td></tr></table>

C. Precision - Fingerstick Samples

In order to estimate precision components for fingerstick samples, data from three studies are combined.

1) Within run precision estimates from accuracy study (Study A) Duplicate measurements of fingerstick samples from 172 subjects were conducted as part of the external accuracy study. The study was conducted at three sites, using three lots of test cartridges. Two lots were assigned to each of three study sites and the fingerstick measurements were performed with one replicate from each of the two available lots for each subject. The duplicate analyses were grouped into four bins of %HbA1c levels, and the CV for each bin was initially estimated by taking the Root Mean Square (RMS) of the pairwise SD within each bin and dividing by the mean of each bin. This initial CV estimate includes both the within-run and the between-lot components of variance.

A more detailed analysis was also conducted to separate the Repeatability from the Between-Lot component. Two of the 172 subjects used the same cartridge lot for both fingersticks and were considered unevaluable for estimating the between-lot component of variance; these two subjects were therefore excluded from the ANOVA model (as reported in Table 12.1.25-5 and 12.1.25-6 of the Performance Testing – Clinical).

Table 4: Fingerstick components of variance from Accuracy study (study A)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>SD from ANOVA</td><td rowspan=1 colspan=3>%CV</td></tr><tr><td rowspan=1 colspan=1>%HbA1cRange</td><td rowspan=1 colspan=1>NumberSubjects</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>Between-Lot</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>Between-Lot</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>4.00-5.99</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>5.42</td><td rowspan=1 colspan=1>0.0823</td><td rowspan=1 colspan=1>0.0650</td><td rowspan=1 colspan=1>0.1049</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>1.93</td></tr><tr><td rowspan=1 colspan=1>6.00-6.99</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>6.46</td><td rowspan=1 colspan=1>0.0876</td><td rowspan=1 colspan=1>0.0270</td><td rowspan=1 colspan=1>0.0916</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>1.42</td></tr><tr><td rowspan=1 colspan=1>7.00-9.99</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>7.93</td><td rowspan=1 colspan=1>0.1067</td><td rowspan=1 colspan=1>0.0000</td><td rowspan=1 colspan=1>0.1067</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.35</td></tr><tr><td rowspan=1 colspan=1>≥10</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10.72</td><td rowspan=1 colspan=1>0.0665</td><td rowspan=1 colspan=1>0.0080</td><td rowspan=1 colspan=1>0.0670</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.62</td></tr></table>

The results shown above for the Total $\% \mathrm { C V }$ calculated via ANOVA differ slightly (but not significantly) from the initial CV estimate based on the RMS of the pairwise SD within each bin, also noting that the initial CV estimate included the two subjects (who used the same cartridge lot for both fingersticks).

2) Between run and between day precision from venous whole blood precision study (Study B) Estimates for between run and between day precision on fingerstick samples were derived from the internal precision study on venous whole blood samples described above in section 1A of this summary and were based on the assumption that these components of variation for fingerstick and venous whole blood are essentially the same. Results for between-run and between-day precision for fingerstick samples are therefore taken from the data summarized in Table 4 above for the four levels of HbA1c.

3) Between-instrument and between operator precision estimates (Study C) Fingerstick precision testing was conducted at three sites, utilizing three Alere Afinion™ AS100 Analyzers. Four levels of HbA1c were assessed, with each site targeting five subjects per level. From each subject three operators collected two fingerstick samples each and

tested them with one replicate on each of two instruments. One of the sites, at the Medium levels enrolled 6 subjects prior to the close of the study. This resulted in six fingerstick sample results from each subject, a total of 15 subjects per level (or 16 subjects per level) and total of 90 fingerstick measurements per level (or 96 fingerstick measurements per level). The analysis of the Medium level was conducted two ways, with first 15 subjects to fill the level (this was the primary analysis) and with all 16 subjects enrolled (this was the secondary analysis). There was no significant difference between the primary and the secondary results; the results of the secondary analysis (2o) of the Medium level are reported in the summary table below.

Table 5: Precision of fingerstick samples - Fingerstick precision study (Study C)   

<table><tr><td rowspan=2 colspan=1>HbA1cLevel</td><td rowspan=2 colspan=1>GrandMean%HbA1c</td><td rowspan=2 colspan=1>N (M)</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenOperator</td><td rowspan=1 colspan=2>Within-run(Repeatability)</td><td rowspan=1 colspan=2>Total*</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.33</td><td rowspan=1 colspan=1>15 (90)</td><td rowspan=1 colspan=1>0.0076</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.0000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0742</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>0.0745</td><td rowspan=1 colspan=1>1.40</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.51</td><td rowspan=1 colspan=1>15 (90)</td><td rowspan=1 colspan=1>0.0192</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.0000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0811</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>0.0834</td><td rowspan=1 colspan=1>1.28</td></tr><tr><td rowspan=1 colspan=1>Medium (20)</td><td rowspan=1 colspan=1>8.32</td><td rowspan=1 colspan=1>16 (96)</td><td rowspan=1 colspan=1>0.0000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0171</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.0918</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.0934</td><td rowspan=1 colspan=1>1.12</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>12.20</td><td rowspan=1 colspan=1>15 (90)</td><td rowspan=1 colspan=1>0.0570</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.0000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.1389</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>0.1501</td><td rowspan=1 colspan=1>1.23</td></tr></table>

Notes: N (M) is the number of subjects (number of test results). CV is SD from ANOVA divided by Grand Mean. \*Total CV is the sum of squares of between instrument, between operator, and within-run (repeatability).

The combined precision estimates from the three studies are shown in Table 6. For the high HbA1c level, the Repeatability CV is taken from the fingerstick precision study (study C) instead of the accuracy study (study A) due to higher number of subjects and replicates in study C. The total CV $( \% )$ was calculated from each of the individual components of variation as also summarized in Table 6.

Table 6: Precision of fingerstick samples - results from three studies combined   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Fingerstick precision from Accuracy StudyA</td><td rowspan=1 colspan=2>Venous Whole BloodPrecision Study B</td><td rowspan=1 colspan=3>Fingerstick Precision Study C</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>%HbA1cRange</td><td rowspan=1 colspan=1>NSubjects</td><td rowspan=1 colspan=1>Repeatability%CV</td><td rowspan=1 colspan=1>BetweenLot %CV</td><td rowspan=1 colspan=1>BetweenRun %CV</td><td rowspan=1 colspan=1>BetweenDay %CV</td><td rowspan=1 colspan=1>Repeatability %CV</td><td rowspan=1 colspan=1>BetweenInstrument%CV</td><td rowspan=1 colspan=1>BetweenOperator%CV</td><td rowspan=1 colspan=1>*Total%CV</td></tr><tr><td rowspan=1 colspan=1>4.00-5.99</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>2.03</td></tr><tr><td rowspan=1 colspan=1>6.00-6.99</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.58</td></tr><tr><td rowspan=1 colspan=1>7.00-9.99</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>1.49</td></tr><tr><td rowspan=1 colspan=1>≥10</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.30</td></tr></table>

\*The Total CV is based on the sum of squares of the 6 components (Repeatability $\% C \mathrm { V } .$ , Between Lot $\% C \mathrm { V } .$ , Between Run $\% C \mathrm { V }$ , Between Day $\% C \mathrm { V } .$ , Between Instrument $\% C \mathrm { V } .$ , and Between Operator $\% C V$ ). For the %HbA1c Range ${ \ge } 1 0 _ { \cdot }$ , the

Repeatability estimate from study C was used to estimate the Total CV; for all other %HbA1c Ranges the Repeatability estimate from study A was used to estimate the Total CV. The number of test results is 2N per level for study A, 720 per level for study B, and 90 (or 96) per level for Study C.

# D. Precision – Between -Instrument

Between analyzer precision of the Afinion™ HbA1c Dx was evaluated using 14 Alere Afinion™ AS100 Analyzers. Four venous whole blood samples were measured in six replicates on each analyzer with one test cartridge lot for a total of 84 replicates per sample.

Table 7: Between-analyzer results   

<table><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Mean %HbA1c</td><td rowspan=1 colspan=1>Between analyzer SD</td><td rowspan=1 colspan=1>Between analyzer CV (%)</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.46</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.47</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.54</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.85</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1.0</td></tr></table>

# E. Lot-to-lot Variation

The lot-to-lot variation for the Afinion™ HbA1c Dx assay was evaluated using three test cartridge lots and 18 EDTA venous whole blood samples spanning the assay measuring (reportable) range. Each sample was analysed in one replicate with each test cartridge lot on the same Alere Afinion™ AS100 Analyzer. The results from all lots were compared pairwise using Bland-Altman analysis.

Table 8: Lot-to-lot variation results   

<table><tr><td rowspan=1 colspan=1>Comparison</td><td rowspan=1 colspan=1>Relative Bias(%)</td><td rowspan=1 colspan=1>95% Confidence interval ofRelative Bias (%)</td><td rowspan=1 colspan=1>95% Limit of Agreement</td></tr><tr><td rowspan=1 colspan=1>Lot 3 - Lot 1</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>-0.8 to 1.0</td><td rowspan=1 colspan=1>-3.5 to 3.7</td></tr><tr><td rowspan=1 colspan=1>Lot 2 - Lot 1</td><td rowspan=1 colspan=1>-0.17</td><td rowspan=1 colspan=1>-1.1 to 0.8</td><td rowspan=1 colspan=1>-4.0 to 3.6</td></tr><tr><td rowspan=1 colspan=1>Lot 3 - Lot 2</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>-0.9 to 1.4</td><td rowspan=1 colspan=1>-4.4 to 4.9</td></tr></table>

# 2. Method Comparison

The method comparison study was performed using an NGSP secondary reference laboratory method (Tosoh Glycohemoglobin test on the G8 HPLC analyzer) as the

# Abbott

comparator (reference) method. Three production lots of Afinion™ HbA1c Dx test cartridges were evaluated with two lots assigned to each of three study sites. Samples from each study subject were tested with both fingerstick samples and fresh venous EDTA samples in single replicates per lot. A total of 120 subjects were included in the study.

Table 9: Sample distribution   

<table><tr><td rowspan=2 colspan=1>%HbA1c IntervalAlere AfinionTM HbA1c Dx</td><td rowspan=1 colspan=4>Number of subjects</td><td rowspan=2 colspan=1>Total %</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>4.0  5.0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>5.1 - 6.0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>12.5</td></tr><tr><td rowspan=1 colspan=1>6.1 - 6.5</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>25.0</td></tr><tr><td rowspan=1 colspan=1>6.6- 7.0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>25.0</td></tr><tr><td rowspan=1 colspan=1>7.1  8.0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>16.7</td></tr><tr><td rowspan=1 colspan=1>8.1 - 9.0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>9.1  15.0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>100.0</td></tr></table>

Table 10: Weighted Deming regression – combined results from 3 sites and 3 lots   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Weighted DemingRegression</td><td rowspan=1 colspan=2>Passing-Bablok Regression</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Fingersticksamples</td><td rowspan=1 colspan=1>Venous wholeblood</td><td rowspan=1 colspan=1>Fingersticksamples</td><td rowspan=1 colspan=1>Venous wholeblood</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>1.000</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>-0.040</td><td rowspan=1 colspan=1>-0.030</td></tr><tr><td rowspan=1 colspan=1>Correlation coefficient(r)</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>0.990</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>0.990</td></tr><tr><td rowspan=1 colspan=1>Number of samples</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>120</td></tr><tr><td rowspan=1 colspan=1>Results range Afinion(%HbA1c)</td><td rowspan=1 colspan=1>4.66 to 11.58</td><td rowspan=1 colspan=1>4.72 to 11.49</td><td rowspan=1 colspan=1>4.66 to 11.58</td><td rowspan=1 colspan=1>4.72 to 11.49</td></tr></table>

# 3. Total Error

For fingerstick samples the results of bias estimation (%Bias) from the accuracy study and the combined precision estimates for fingerstick samples from three studies were used for calculation of the Total Error (TE) at four concentrations (5.0, 6.5, 8.0 and $1 2 . 0 ~ \%$ HbA1c). These results are shown in Table 11.

For venous whole blood, the results of bias estimation (%Bias) from the accuracy study and precision estimates in the internal precision study using three lots and three Alere

# Abbott

Afinion™ Analyzers over 20 days, were used for calculation of the Total Error (TE) at four concentrations of HbA1c (5.0, 6.5, 8.0 and $1 2 . 0 \%$ ). These results are shown in Table 12.

For venous whole blood, the Total Error (TE) was also estimated by a second method, similar those described above, but where the precision estimates are from the external precision study, as described in Table 3, which also includes the Between Analyzer component of variance from the internal study. These results are shown in Table 13, labeled as “Total error - venous whole blood samples at the Point of Care” to distinguish these estimates from those in Table 12.

The acceptable %TE is $\le 6 . 0 \%$ . (Refer to Section 12.4 of the Performance Testing – Clinical for the Total Error formula.)

Table 11: Total error – fingerstick whole blood samples   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Weighted Deming Regression</td><td rowspan=1 colspan=3>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>%HbA1c Level</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-0.335</td><td rowspan=1 colspan=1>2.03</td><td rowspan=1 colspan=1>4.30</td><td rowspan=1 colspan=1>-0.800</td><td rowspan=1 colspan=1>2.03</td><td rowspan=1 colspan=1>4.75</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-0.334</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>3.42</td><td rowspan=1 colspan=1>-0.615</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>3.69</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-0.334</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>3.24</td><td rowspan=1 colspan=1>-0.500</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>3.40</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>-0.333</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>-0.333</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>2.87</td></tr></table>

Table 12: Total error - venous whole blood samples   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Weighted Deming Regression</td><td rowspan=1 colspan=3>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>%HbA1c Level</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.195</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>3.42</td><td rowspan=1 colspan=1>-0.600</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>3.80</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-0.052</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>3.01</td><td rowspan=1 colspan=1>-0.462</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>3.41</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-0.206</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>2.77</td><td rowspan=1 colspan=1>-0.375</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>2.93</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>-0.429</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>3.20</td><td rowspan=1 colspan=1>-0.250</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>3.03</td></tr></table>

Table 13: Total error - venous whole blood samples at the Point of Care   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Weighted Deming Regression</td><td rowspan=1 colspan=3>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>%HbA1c Level</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.195</td><td rowspan=1 colspan=1>1.78</td><td rowspan=1 colspan=1>3.69</td><td rowspan=1 colspan=1>-0.600</td><td rowspan=1 colspan=1>1.78</td><td rowspan=1 colspan=1>4.07</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-0.052</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>2.95</td><td rowspan=1 colspan=1>-0.462</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>3.35</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-0.206</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>-0.375</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>3.03</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>-0.429</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>2.81</td><td rowspan=1 colspan=1>-0.250</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>2.64</td></tr></table>

# 4. Endogenous Interference

Six endogenous substances spiked into whole blood sample pools were evaluated for potential assay interference in accordance with CLSI guideline EP07-A2. Two HbA1c levels, one near the medical decision level and one above it, were tested for each endogenous substance. Each sample was tested for %HbA1c with ten replicates on a single

Alere Afinion™ AS100 Analyzer, using a single test cartridge lot. The corresponding nonspiked sample which contained no added substance was also tested with ten replicates. A mean was calculated for each set of ten. Significant interference was defined as exceeding a $7 \%$ change in %HbA1c value from the control (non-spiked sample). The results for the spiked samples were compared to the control with no interference at the stated concentrations.

Table 14: Endogenous interference results   

<table><tr><td rowspan=1 colspan=1>Endogenous substance</td><td rowspan=1 colspan=1>Test concentration with no significant interference</td></tr><tr><td rowspan=1 colspan=1>Bilirubin, conjugated</td><td rowspan=1 colspan=1>600 mg/L</td></tr><tr><td rowspan=1 colspan=1>Bilirubin, unconjugated</td><td rowspan=1 colspan=1>600 mg/L</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>10 000 mg/L</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>10 000 mg/L</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid factor</td><td rowspan=1 colspan=1>780 000 IU/L</td></tr><tr><td rowspan=1 colspan=1>Total protein</td><td rowspan=1 colspan=1>15 g/dL</td></tr></table>

# 5. Hemolysis Interference

Potential assay interference from hemolysis was assessed in accordance with CLSI guideline EP07-A2. Whole blood samples with two HbA1c levels, one near the medical decision level and one above it, were used for the testing. Hemolysis in the blood samples was simulated by spiking with fresh hemolysate prepared from the native samples. Hemolysate was added to the corresponding native sample to volume percentages of 5, 10, 15 and $2 0 \%$ . The exact degree of hemolysis was measured in each spiked fraction. Each spiked sample and corresponding non-spiked sample was tested in ten replicates on a single Alere Afinion™ AS100 analyzer using one test cartridge lot. The mean result from the manipulated sample was compared to the mean result from the corresponding native control sample. Significant interference was defined as exceeding a $7 \%$ change in $\%$ HbA1c value from the control (native sample). The results demonstrated no interference up to $2 4 \%$ hemolysis, however at hemolysis above $1 4 \%$ $( 2 0 0 0 \mathrm { m g / d L } )$ information codes related to hemolysis may occur with a frequency which increases with increasing degrees of hemolysis.

# 6. Drug Interference

Twenty drugs spiked into whole blood sample pools were tested for potential assay interference in accordance with CLSI guideline EP7-A2. The drug substances included commonly used antibiotics, analgesic agents, immunosupressants, anti-inflammatory drugs, anticoagulants and prescription drugs for diabetes treatment. Two HbA1c levels, one near the medical decision level and one above it, were tested for each endogenous substance. Each spiked sample was tested for %HbA1c in ten replicates on a single Alere Afinion™ AS100 Analyzer, using a single test cartridge lot. The corresponding non-spiked

# Abbott

sample which contained no added substance was also tested with ten replicates. A mean was calculated for each set of ten. Significant interference was defined as exceeding a $7 \%$ change in %HbA1c value from the control (non-spiked sample). The results for the spiked samples were compared to the control with no interference at the stated concentrations.

Table 15: Drug interference results   

<table><tr><td rowspan=1 colspan=1>Drug substance</td><td rowspan=1 colspan=1>Test concentration with no significantinterference (mg/L)</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Acetylcysteine</td><td rowspan=1 colspan=1>1663</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>300</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>2500</td></tr><tr><td rowspan=1 colspan=1>Metformin</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine C</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Glyburide</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Doxycycline</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine A</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5000 U/L</td></tr><tr><td rowspan=1 colspan=1>Salicylic acid</td><td rowspan=1 colspan=1>599</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>400</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>64</td></tr></table>

# 7. Cross reactivity with Hemoglobin Derivatives

Potential assay interference from hemoglobin derivatives was assessed in accordance with CLSI guideline EP07-A2. Whole blood samples with two HbA1c levels, one near the medical decision level and one above it, were used for the testing. For each HbA1c level, two whole blood pools were prepared for each derivative, one without derivative (control) and one with high concentration of derivative. Each sample was tested in ten replicates on a single Alere Afinion™ AS100 Analyzer using one test cartridge lot. A mean was calculated for each set of ten. Significant interference was defined as exceeding a $7 \%$ change in %HbA1c value from the control (non-spiked sample). The results for the spiked samples were compared to the control with no interference at the stated concentrations.

Table 16: Cross reactivity with hemoglobin derivatives results   

<table><tr><td rowspan=1 colspan=1>Hemoglobin derivative</td><td rowspan=1 colspan=1>Test concentration with no significantinterference</td></tr><tr><td rowspan=1 colspan=1>Acetylated hemoglobin</td><td rowspan=1 colspan=1>4.6 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Carbamylated hemoglobin</td><td rowspan=1 colspan=1>13.8 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Labile HbA1c</td><td rowspan=1 colspan=1>11.4 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Glycated albumin</td><td rowspan=1 colspan=1>7.7 mg/mL</td></tr></table>

# 8. Hemoglobin Variants Interference

Potential assay interference from hemoglobin variants was evaluated in accordance with CLSI guideline EP07-A2. A total of 234 fresh EDTA whole blood samples that contained one of six common hemoglobin variants were included in the study. All samples were tested by the Afinion™ HbA1c $\mathrm { D x }$ and with an NGSP reference method that is known to be free from the hemoglobin interference being tested. The level of Hb variant was determined by the Capillarys 2 Flex Piercing method. Interference effect was assessed by comparing the HbA1c results from Afinion HbA1c Dx to the reference method result for samples with potentially interfering hemoglobin variants. Significant interference was defined as exceeding a $7 \%$ change in %HbA1c value from the reference method.

Cross-reactivity from HbA0, HbA1a and HbA1b components was also evaluated in a study including 100 samples with characterization of these fractions and comparison to a reference method (Tosoh G8 HPLC).

Table 16 indicates the number, range and concentration of samples and Table 17 summarizes the results from the study.

Table 17: Sample profile for hemoglobin variant study   

<table><tr><td rowspan=1 colspan=1>HemoglobinVariant</td><td rowspan=1 colspan=1>Number ofsamples</td><td rowspan=1 colspan=1>Range of % content ofvariant</td><td rowspan=1 colspan=1>Range of concentrationin %HbA1c</td></tr><tr><td rowspan=1 colspan=1>HbA0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>82-95</td><td rowspan=3 colspan=1>4.27-13.93</td></tr><tr><td rowspan=1 colspan=1>HbA1a</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0.4-1.4</td></tr><tr><td rowspan=1 colspan=1>HbA1b</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0.4-2.3</td></tr><tr><td rowspan=1 colspan=1>HbA2</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>3.9-5.7</td><td rowspan=1 colspan=1>5.8-10.6</td></tr><tr><td rowspan=1 colspan=1>HbS</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>35-42</td><td rowspan=1 colspan=1>5.6-8.8</td></tr><tr><td rowspan=1 colspan=1>HbC</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>30-36</td><td rowspan=1 colspan=1>5.5-9.7</td></tr><tr><td rowspan=1 colspan=1>HbE</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>17-26</td><td rowspan=1 colspan=1>6.1-8.9</td></tr><tr><td rowspan=1 colspan=1>HbD</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>27-42</td><td rowspan=1 colspan=1>6.1-9.4</td></tr><tr><td rowspan=1 colspan=1>HbF</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>3.4-28.1</td><td rowspan=1 colspan=1>5.0-11.3</td></tr></table>

Table 18: Hemoglobin variant results   

<table><tr><td rowspan=3 colspan=1>HemoglobinVariant</td><td rowspan=1 colspan=4>Percent relative bias from reference method at two levels of the HbA1csamples</td></tr><tr><td rowspan=1 colspan=2>Level 1: ~6.5 %HbA1c</td><td rowspan=1 colspan=2>Level 2: ~8.5 %HbA1c</td></tr><tr><td rowspan=1 colspan=1>Mean Relativebias (%)</td><td rowspan=1 colspan=1>Range%Bias^</td><td rowspan=1 colspan=1>Mean Relativebias (%)</td><td rowspan=1 colspan=1>Range %Bias^</td></tr><tr><td rowspan=1 colspan=1>HbA0</td><td rowspan=3 colspan=1>0.1</td><td rowspan=3 colspan=1>-6.1, 8.5</td><td rowspan=3 colspan=1>-0.4</td><td rowspan=3 colspan=1>-6.0, 6.7</td></tr><tr><td rowspan=1 colspan=1>HbA1a</td></tr><tr><td rowspan=1 colspan=1>HbA1b</td></tr><tr><td rowspan=1 colspan=1>HbA2</td><td rowspan=1 colspan=1>-3.4</td><td rowspan=1 colspan=1>-6.2, -1.3</td><td rowspan=1 colspan=1>-2.5</td><td rowspan=1 colspan=1>-6.6, 2.8</td></tr><tr><td rowspan=1 colspan=1>HbS</td><td rowspan=1 colspan=1>-4.1</td><td rowspan=1 colspan=1>-6.6, 3.2</td><td rowspan=1 colspan=1>-1.0</td><td rowspan=1 colspan=1>-9.9, 3.5</td></tr><tr><td rowspan=1 colspan=1>HbC</td><td rowspan=1 colspan=1>-5.5</td><td rowspan=1 colspan=1>-8.5, -1.8</td><td rowspan=1 colspan=1>-1.8</td><td rowspan=1 colspan=1>-5.2, 1.1</td></tr><tr><td rowspan=1 colspan=1>HbE</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.4, 7.9</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.0, 4.7 (14.0*)</td></tr><tr><td rowspan=1 colspan=1>HbD</td><td rowspan=1 colspan=1>-2.2</td><td rowspan=1 colspan=1>-4.1, 0.0</td><td rowspan=1 colspan=1>-2.9</td><td rowspan=1 colspan=1>-5.9, 0.0</td></tr><tr><td rowspan=1 colspan=1>HbF</td><td rowspan=1 colspan=4>10.4% HbF is the highest HbF concentration where no significant interference isobserved with significant interference defined as &gt; ±7%. </td></tr></table>

^The range is defined as the minimum and maximum relative $\%$ difference at each concentration level. ^^ A negative relative bias with HbF has increasing magnitude with HbF and also with increasing %HbA1c. \*One single outlier for a sample with HbE level of $2 2 . 8 \%$ .

No significant interference was observed for the HbA2, HbS, HbC, HbE and HbD. For HbF interference, the device includes the following prominent boxed warning:

This device has significant negative interference with fetal hemoglobin (HbF). HbA1c results are invalid for patients with abnormal amounts of HbF including those with known Heredity Persistence of Fetal Hemoglobin. Refer to the Analytical specificity and Limitations sections in this package insert for details.

# 9. Linearity

The linearity of the Alere Afinion™ HbA1c assay was previously established in k050574, and was not re-established for the additional indications for use for the Afinion™ HbA1c Dx assay. The reportable range for this device is $4 . 0 0 { - } 1 5 . 0 0 \%$ HbA1c (DCCT/NGSP).

# CONCLUSION

The information and data in this 510(k) application demonstrate that the Afinion™ HbA1c Dx assay is an accurate and precise test that correlates well with current cleared methods and is NGSP standardized for the quantitation of HbA1c. Performance criteria as outlined in the special control requirements of 21 CFR 862.1373 for the diagnosis of diabetes have been met. Based on the criteria stated above, this device is found to be substantially equivalent to the predicate device.